PERIOP 2 - A Safety and Effectiveness of LMWH vs Placebo Bridging Therapy for Patients on Long Term Warfarin Requiring Temporary Interruption of Warfarin.

PHASE3UnknownINTERVENTIONAL
Enrollment

1,473

Participants

Timeline

Start Date

December 31, 2006

Primary Completion Date

March 31, 2019

Study Completion Date

December 31, 2020

Conditions
Stroke
Interventions
DRUG

Dalteparin

5,000 iu or 200 iu/kg depending on the type of surgery injection will be given subcutaneously, once a day for a minimum of 4 days or until the INR is 2.0

OTHER

Placebo

"patients will be randomized post-operative to receive either active treatment or placebo.~the placebo will be given as a subcutaneous injection once a day. the amount of the placebo will be equivalent to the active treatment depending on the type of surgery.~ie. 5,000 iu or 200 iu/kg"

Trial Locations (8)

110060

Sir Ganga Ram Hospital, New Delhi

500001

Care Hospital, Hyderabad

B3H 2Y9

QE II Health Sciences Centre, Halifax

L8L 2X2

Hamilton Health Sciences Corporation-General Hospital, Hamilton

L8N 3Z5

Hamilton Health Sciences Corporation-McMaster Site, Hamilton

L8V 1C3

Hamilton Health Sciences Corporation-Henderson Site, Hamilton

K1H 8L6

Ottawa Hospital-General Campus, Ottawa

H3T 1E2

SMBD Jewish General Hospital, Montreal

Sponsors

Collaborators (1)

All Listed Sponsors
collaborator

Canadian Institutes of Health Research (CIHR)

OTHER_GOV

collaborator

Pfizer

INDUSTRY

lead

London Health Sciences Centre Research Institute OR Lawson Research Institute of St. Joseph's

OTHER